3 completed, 1 unknown. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 3, Unknown 1 |
Follow SARS CoV 2 Infection: new trials by email Literature Review of SARS CoV 2 Infection trials Research Report on SARS CoV 2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Novavax | 660 | 2024-09-19 | 2026-06-02 |
| The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing) - COVID-19, Vaccine-Preventable Diseases | Phase 4 | Completed | Sarang K. Yoon, DO, MOH | 1188 | 2023-11-22 | 2026-01-28 |
| The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals BioBlock® antiviral nasal spray - SARS CoV 2 Infection | Phase 4 | Unknown | Chemi-Pharm AS | 2000 | 2022-05-01 | 2023-02-08 |
| A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) Vaccines. Johnson & Johnson - SARS CoV 2 Infection | Phase 4 | Completed | Jens D Lundgren, MD | 25 | 2021-07-05 | 2024-04-11 |
COVID-19 (4) · Vaccine-Preventable Diseases (2) · Respiration Disorders (1) · Respiratory Tract Infections (1)
Coronaviridae Infections (4) · Coronavirus Infections (4) · Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Virus Diseases (4) · Respiratory Tract Infections (3)
Ad26COVS1 (1) · NVX-CoV2373 adjuvated lipid nanoparticle (1)
Chemi-Pharm AS (1) · Jens D Lundgren, MD (1) · Novavax (1) · Sarang K. Yoon, DO, MOH (1)
United States (2) · Denmark (1) · Estonia (1)
Jens Lundgren, Professor (1) · Sarang K Yoon, DO (1) · Sarang K Yoon, MOH (1)